Evidence map›Paper›PMID 28574763›Full record

ArticleFly2017

The dark side of hippo signaling: A cancer promoter role.

Brandon Dunn, Xianjue Ma

Open access · bronzeAbstract read
In one paragraph

Article in Fly, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. POSH regulates Hippo signaling through ubiquitin-mediated expanded degradation.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Brandon Dunna Howard Hughes Medical Institute , Department of Genetics , Yale University School of Medicine , New Haven , CT , USA.ORCID 0000-0003-4374-0968
Xianjue Maa Howard Hughes Medical Institute , Department of Genetics , Yale University School of Medicine , New Haven , CT , USA.
Howard Hughes Medical Institute · USTongji University · CN

Funding

Training Program in Molecular MedicineT32GM100884 · NIGMS · YALE UNIVERSITY · PI LISTER, GEORGE, NITABACH, MICHAEL · 2013 to 2022
$1.8M
NIGMS NIH HHS T32 GM100884
6 · The paper itself

Abstract

The Hippo signaling pathway regulates organ size and tissue homeostasis. Given this role it is unsurprising that dysregulation of this pathway has implications for cancer progression. A convincing body of literature shows that the Hippo pathway serves a tumor suppressive function with its inactivation leading to massive overgrowth. However, additional studies have also shown that activation of Hippo signaling can promote tumor progression. It remains unknown how a single pathway can produce such diametrically opposed effects. This lack of knowledge is in part due to our inability to make meaningful comparisons from studies which have taken place in a variety of cell types, tissues, and organisms. Recently however, we have published 2 studies using the Drosophila wing disk to study the Hippo pathway and have found that Hippo pathway activation can promote cell migration and invasion while Hippo pathway inactivation leads to overgrowth. Thus we propose here that Drosophila can provide a research platform with which to begin addressing how the Hippo pathway can both enhance and suppress tumor progression due to published pro- and anti-tumor functionalities of the Hippo pathway in the same tissue.

Indexed as

Signal TransductionAnimalsCarcinogenesisDisease Models, AnimalDrosophila melanogasterDrosophila ProteinsGene Expression Regulation, NeoplasticHippo KinasesHumansIntracellular Signaling Peptides and ProteinsNeoplasmsNuclear ProteinsProtein Serine-Threonine KinasesTrans-ActivatorsYAP-Signaling ProteinsDrosophila ProteinsHippo Kinaseshpo protein, DrosophilaIntracellular Signaling Peptides and ProteinsNuclear ProteinsProtein Serine-Threonine KinasesTrans-ActivatorsYAP-Signaling ProteinsYki protein, Drosophilacell invasionDrosophilaHippo pathwayJNK pathwaytumorigenesis

Identifiers

PMID28574763
PMCPMC5721939
OpenAlexW2620934543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.